{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:32:17Z","timestamp":1783632737481,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s10147-021-02021-8","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T14:06:01Z","timestamp":1630505161000},"page":"2275-2281","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience"],"prefix":"10.1007","volume":"26","author":[{"given":"Masaki","family":"Uchihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6558-2246","authenticated-orcid":false,"given":"Maki","family":"Tanioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadaaki","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Shimoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko Miyagi","family":"Maeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Yonemori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"key":"2021_CR1","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s00268-005-0329-x","volume":"30","author":"E Kebebew","year":"2006","unstructured":"Kebebew E, Reiff E, Duh QY et al (2006) Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg 30:872\u2013878. https:\/\/doi.org\/10.1007\/s00268-005-0329-x","journal-title":"World J Surg"},{"key":"2021_CR2","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1016\/j.ejca.2013.02.034","volume":"49","author":"TMA Kerkhofs","year":"2013","unstructured":"Kerkhofs TMA, Verhoeven RHA, Van der Zwan JM et al (2013) Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer 49:2579\u20132586. https:\/\/doi.org\/10.1016\/j.ejca.2013.02.034","journal-title":"Eur J Cancer"},{"key":"2021_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1530\/EJE-18-0608","volume":"10","author":"M Fassnacht","year":"2018","unstructured":"Fassnacht M, Dekkers OM, Else T et al (2018) European journal of endocrinology European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors. Guillaume Assie 10:19. https:\/\/doi.org\/10.1530\/EJE-18-0608","journal-title":"Guillaume Assie"},{"key":"2021_CR4","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","volume":"366","author":"M Fassnacht","year":"2012","unstructured":"Fassnacht M, Terzolo M, Allolio B et al (2012) Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 366:2189\u20132197. https:\/\/doi.org\/10.1056\/NEJMoa1200966","journal-title":"N Engl J Med"},{"key":"2021_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/bmjspcare-2018-001568","volume":"9","author":"M Shuayb","year":"2019","unstructured":"Shuayb M, Das A, Uddin MN (2019) Long-term survival in recurrent adrenocortical cancer. BMJ Support Palliat Care 9:47\u201350. https:\/\/doi.org\/10.1136\/bmjspcare-2018-001568","journal-title":"BMJ Support Palliat Care"},{"key":"2021_CR6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1530\/EJE-15-0354","volume":"173","author":"F Ferra\u00f9","year":"2015","unstructured":"Ferra\u00f9 F, Rta Korbonits M (2015) Metabolic comorbidities in Cushing\u2019s syndrome. Eur J Endocrinol 173:133\u2013157. https:\/\/doi.org\/10.1530\/EJE-15-0354","journal-title":"Eur J Endocrinol"},{"key":"2021_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0645-6","author":"ST Sharma","year":"2015","unstructured":"Sharma ST, Nieman LK, Feelders RA (2015) Comorbidities in Cushing\u2019s disease. Pituitary 18:188\u2013194. https:\/\/doi.org\/10.1007\/s11102-015-0645-6","journal-title":"Pituitary"},{"key":"2021_CR8","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.21037\/jtd.2019.08.63","volume":"12","author":"LJ Li","year":"2020","unstructured":"Li LJ, Chong Q, Wang L et al (2020) Different treatment efficacies and side effects of cytotoxic chemotherapy. J Thorac Dis 12:3785\u20133795. https:\/\/doi.org\/10.21037\/jtd.2019.08.63","journal-title":"J Thorac Dis"},{"key":"2021_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.06.027","author":"HS Han","year":"2011","unstructured":"Han HS, Reis IM, Zhao W et al (2011) Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer. Eur J Cancer 47(17):2537\u20132545. https:\/\/doi.org\/10.1016\/j.ejca.2011.06.027","journal-title":"Eur J Cancer"},{"key":"2021_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"2021_CR11","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0452","author":"G Reimondo","year":"2017","unstructured":"Reimondo G, Puglisi S, Zaggia B et al (2017) Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma. Eur J Endocrinol 177(4):361\u2013367. https:\/\/doi.org\/10.1530\/EJE-17-0452","journal-title":"Eur J Endocrinol"},{"key":"2021_CR12","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-08-0103","author":"F Daffara","year":"2008","unstructured":"Daffara F, De Francia S, Reimondo G et al (2008) Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer. https:\/\/doi.org\/10.1677\/ERC-08-0103","journal-title":"Endocr Relat Cancer"},{"key":"2021_CR13","doi-asserted-by":"publisher","DOI":"10.1530\/edm-16-0061","author":"E Flynn","year":"2016","unstructured":"Flynn E, Baqar S, Liu D et al (2016) Bowel perforation complicating an ACTH-secreting phaeochromocytoma. Endocrinol Diabetes Metab Case Rep. https:\/\/doi.org\/10.1530\/edm-16-0061","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"2021_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s12020-017-1428-9","volume":"61","author":"M Claps","year":"2020","unstructured":"Claps M, Cerri S, Grisanti S et al (2020) Adding metyrapone to chemotherapy plus mitotane for Cushing\u00e2\u20acTMs syndrome due to advanced adrenocortical carcinoma. Endocrine 61:169\u2013172. https:\/\/doi.org\/10.1007\/s12020-017-1428-9","journal-title":"Endocrine"},{"key":"2021_CR15","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1530\/EJE-18-0450","volume":"179","author":"T Vanbrabant","year":"2018","unstructured":"Vanbrabant T, Fassnacht M, Assie G et al (2018) Influence of hormonal functional status on survival in adrenocortical carcinoma: systematic review and meta-analysis. Eur J Endocrinol 179:429\u2013436","journal-title":"Eur J Endocrinol"},{"key":"2021_CR16","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.eururo.2013.11.006","volume":"65","author":"A Berruti","year":"2014","unstructured":"Berruti A, Fassnacht M, Haak H et al (2014) Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. Eur Urol 65:832\u2013838. https:\/\/doi.org\/10.1016\/j.eururo.2013.11.006","journal-title":"Eur Urol"},{"key":"2021_CR17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1001\/jamasurg.2015.4516","volume":"151","author":"Y Kim","year":"2016","unstructured":"Kim Y, Margonis GA, Prescott JD et al (2016) Nomograms to predict recurrence-free and overall survival after curative resection of adrenocortical carcinoma. JAMA Surg 151:365\u2013373. https:\/\/doi.org\/10.1001\/jamasurg.2015.4516","journal-title":"JAMA Surg"},{"issue":"6","key":"2021_CR18","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/1097-0142(20010915)92:6<1385::aid-cncr1461>3.0.co;2-2","volume":"92","author":"E Baudin","year":"2001","unstructured":"Baudin E, Pellegriti G, Bonnay M et al (2001) Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o, pDDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92(6):1385\u20131392. https:\/\/doi.org\/10.1002\/1097-0142(20010915)92:6%3c1385::aid-cncr1461%3e3.0.co;2-2","journal-title":"Cancer"},{"key":"2021_CR19","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1210\/jc.2010-2676","volume":"96","author":"IG Hermsen","year":"2011","unstructured":"Hermsen IG, Fassnacht M, Terzolo M et al (2011) Plasma concentrations of o, pDDD, o, pDDA, and o, pDDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 96:1844\u20131851. https:\/\/doi.org\/10.1210\/jc.2010-2676 (jcem.endojournals.org)","journal-title":"J Clin Endocrinol Metab"},{"key":"2021_CR20","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3390\/biomedicines9020174","volume":"9","author":"M Mizdrak","year":"2021","unstructured":"Mizdrak M, Ti\u010dinovi\u0107 Kurir T, Bo\u017ei\u0107 J (2021) The role of biomarkers in adrenocortical carcinoma: a review of current evidence and future perspectives. Biomedicines 9:174. https:\/\/doi.org\/10.3390\/biomedicines9020174","journal-title":"Biomedicines"},{"key":"2021_CR21","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","volume":"16","author":"M Fassnacht","year":"2015","unstructured":"Fassnacht M, Berruti A, Baudin E et al (2015) Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol 16:426\u2013435. https:\/\/doi.org\/10.1016\/S1470-2045(15)70081-1","journal-title":"Lancet Oncol"},{"key":"2021_CR22","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1210\/jc.2013-2298","volume":"99","author":"M Edgerly","year":"2014","unstructured":"Edgerly M, Velarde M, Wilkerson J et al (2014) The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. J Clin Endocrinol Metab 99:1291\u20131297. https:\/\/doi.org\/10.1210\/jc.2013-2298","journal-title":"J Clin Endocrinol Metab"},{"key":"2021_CR23","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0918","author":"A Berruti","year":"2012","unstructured":"Berruti A, Sperone P, Ferrero A et al (2012) Phase II study of weekly paclitaxel and sorafenib as second\/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol 166(3):451\u2013458. https:\/\/doi.org\/10.1530\/EJE-11-0918","journal-title":"Eur J Endocrinol"},{"key":"2021_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0424-9","author":"C Le Tourneau","year":"2018","unstructured":"Le Tourneau C, Hoimes C, Zarwan C et al (2018) Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. J Immunother Cancer 6(1):111. https:\/\/doi.org\/10.1186\/s40425-018-0424-9","journal-title":"J Immunother Cancer"},{"key":"2021_CR25","doi-asserted-by":"publisher","DOI":"10.1530\/EC-18-0398","author":"D Cosentini","year":"2018","unstructured":"Cosentini D, Grisanti S, Dalla Volta A et al (2018) Immunotherapy failure in adrenocortical cancer: where next? Endocr Connect 7(12):E5\u2013E8. https:\/\/doi.org\/10.1530\/EC-18-0398","journal-title":"Endocr Connect"},{"key":"2021_CR26","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1677\/ERC-08-0224","volume":"16","author":"CL Ronchi","year":"2009","unstructured":"Ronchi CL, Sbiera S, Kraus L et al (2009) Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocr Relat Cancer 16:907\u2013918. https:\/\/doi.org\/10.1677\/ERC-08-0224","journal-title":"Endocr Relat Cancer"},{"key":"2021_CR27","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-09-0341","author":"P Malandrino","year":"2010","unstructured":"Malandrino P, Al Ghuzlan A, Castaing M et al (2010) Prognostic markers of survival after combined mitotane-and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocr Relat Cancer 17(3):797\u2013807. https:\/\/doi.org\/10.1677\/ERC-09-0341","journal-title":"Endocr Relat Cancer"},{"key":"2021_CR28","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0095","author":"E Roca","year":"2017","unstructured":"Roca E, Berruti A, Sbiera S et al (2017) Topoisomerase 2\u03b1 and thymidylate synthase expression in adrenocortical cancer. Endocr Relat Cancer 24(7):319\u2013327. https:\/\/doi.org\/10.1530\/ERC-17-0095","journal-title":"Endocr Relat Cancer"},{"key":"2021_CR29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1530\/EJE-17-0788","volume":"178","author":"V Laufs","year":"2018","unstructured":"Laufs V, Altieri B, Sbiera S et al (2018) ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas. Eur J Endocrinol 178:181\u2013188. https:\/\/doi.org\/10.1530\/EJE-17-0788","journal-title":"Eur J Endocrinol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-02021-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-021-02021-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-02021-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T02:03:04Z","timestamp":1636596184000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-021-02021-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2021"],"URL":"https:\/\/doi.org\/10.1007\/s10147-021-02021-8","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]},"assertion":[{"value":"17 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}